Lucentis (Ranibizumab injection)
Lucentis® (ranibizumab injection) is indicated for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion.
* Sold in the US via Genentech,
outside the United States Lucentis is marketed by Novartis
Looking for more detailed information?
For regulatory reasons we are not able to provide further details on our products on this website, but more information may be available on our local website.
Please choose your country of residence to access available information in your language.